EU/3/12/964

About

On 23 April 2012, orphan designation (EU/3/12/964) was granted by the European Commission to Dafra Pharma International NV, Belgium, for oleylphosphocholine for the treatment of leishmaniasis.

The sponsorship was transferred to Oblita Therapeutics, Belgium in August 2016.

Key facts

Active substance
Oleylphosphocholine
Disease / condition
Treatment of leishmaniasis
Date of first decision
23/04/2012
Outcome
Positive
EU designation number
EU/3/12/964

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Oblita Therapeutics
Rodendijk 40
2980 Zoersel
Belgium

 

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating